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Aging is the major risk factor per se for the development of cardiovascular diseases. The
senescence of the endothelial cells (ECs) that line the lumen of blood vessels is the cel-
lular basis for these age-dependent vascular pathologies, including atherosclerosis and
hypertension. During their lifespan, ECs may reach a stage of senescence by two different
pathways; a replicative one derived from their preprogrammed ﬁnite number of cell divi-
sions; and one induced by stress stimuli. Also, certain physiological stimuli, such as trans-
forming growth factor-β, are able to modulate cellular senescence. Currently, the cellular
aging process is being widely studied to identify novel molecular markers whose changes
correlate with senescence. This review focuses on the regulation of alternative splicing
mediated by the serine–arginine splicing factor 1 (SRSF1, or ASF/SF2) during endothe-
lial senescence, a process that is associated with a differential subcellular localization of
SRSF1, which typically exhibits a scattered distribution throughout the cytoplasm. Based
on its senescence-dependent involvement in alternative splicing, we postulate that SRSF1
is a key marker of EC senescence, regulating the expression of alternative isoforms of
target genes such as endoglin (ENG), vascular endothelial growth factor A (VEGFA), tissue
factor (T3), or lamin A (LMNA) that integrate in a common molecular senescence program.
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INTRODUCTION
It is well established that vascular physiology declines with aging
due to the impairment of endothelial functions. This endothelial
dysfunction is fairly evidenced by the stiffening of blood vessels
that fail to control the dilatory responses associatedwith hyperten-
sion (Versari et al., 2009), and by a pro-inﬂammatory state of the
endothelialmicroenvironment that favors the development of ath-
erosclerosis (Erusalimsky, 2009). Hence the biology of endothelial
cells (ECs) is a key element for elucidating and understanding
the cellular and molecular basis of vascular pathologies associated
with age.
Endothelial cells forma thinmonolayer that lines the blood ves-
sels and is in direct contact with the blood ﬂow. During embryonic
development, processes including vasculogenesis and angiogene-
sis require repeated division of ECs, but in adults these cells are
in a quiescent state and divide only occasionally (Conway and
Carmeliet, 2004; Semenza, 2007; Carmeliet and Jain, 2011). How-
ever, at this latter stage ECs remain highly responsive tomechanical
stimuli, such as shear stress and injuries, as well as to chemical
signals, including hypoxia, cytokines, and growth factors, among
others. Thus, during vascular remodeling or upon angiogenic
stimulation, ECs actively proliferate, but progressively lose their
capacity to divide, reaching the stage of replicative senescence.
This process involves telomere shortening until the cells reach the
so-called Hayﬂick’s limit (Brandes et al., 2005), that renders cell
division impossible, constituting a mechanism to prevent genomic
instability and the development of cancer (Shay and Wright,
2007). Endothelial senescence can also be triggered by telomere-
independent events, including chemotherapy, proto-oncogene-
induced senescence, alterations in nuclear lamina, and stress stim-
uli that usually involve DNA damage. In this sense, oxidative stress
and ultraviolet radiation are major stimuli for the induction of
this type of senescence; both ultimately generate reactive oxy-
gen species (ROS; Debacq-Chainiaux et al., 2005; Erusalimsky and
Skene, 2009; Collins and Tzima, 2011) and activate retinoblastoma
protein family pathways, the ﬁnal effectors of the senescence pro-
gram (Campisi and d’Adda di Fagagna, 2007; Erusalimsky, 2009).
There is a growing body of evidence that vascular aging and
senescence of ECs are the basis of the endothelial dysfunction asso-
ciated with vascular pathologies. For example, it is well known that
aging is associated with decreased angiogenesis (Brandes et al.,
2005; Erusalimsky, 2009), and that senescent ECs are unable to
form neoangiogenic networks in matrigel assays (Chang et al.,
2005). In this regard, certain physiological regulators of angio-
genesis, such as transforming growth factor-β (TGF-β), are able
to modulate cellular senescence of ECs (Santibanez et al., 2011;
Blanco and Bernabeu, 2012; Doetschman et al., 2012; Krieglstein
et al., 2012).
Recently, growing interest has focused on the role of alterna-
tive processing of certain precursor mRNA transcripts during EC
senescence (Meshorer and Soreq, 2002; Harries et al., 2011). Alter-
native splicing represents an advantageous mechanism by which
cells enrich their transcriptome in order to synthesize a specialized
proteome for a particular stage or process. An early link between
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the role of alternative splicing and aging was described in the late
1980s, when it was reported that alternative isoforms from the
elastin gene (ELN ) could contribute to aging and pathological sit-
uations in the cardiovascular and pulmonary systems (Indik et al.,
1989). Since then, numerous papers have conﬁrmed this idea, not
only in senescent ECs, but also in other cell types (Meshorer and
Soreq, 2002).
Currently, active investigations are focused on the molecu-
lar components that orchestrate the modulation of alternative
splicing events in aging. Brieﬂy, splicing is carried out by the
spliceosome, a complex molecular machinery integrated by a core
of small nuclear ribonucleoproteins (snRNPs) plus a great vari-
ety of essential and accessory splicing factors, or trans-elements.
These splicing factors recognize short consensus sequences in a
precursor mRNA, or cis-elements, thereby modulating its activ-
ity. Thus, it is assumed that the splicing changes observed during
aging are part of a genetically programmed mechanism which is
not necessarily associated with deleterious mutations, but with the
splicing factors that play a critical role affecting the expression of
target genes.
SPLICING FACTORS INVOLVED IN ENDOTHELIAL
SENESCENCE
Analyses of the splicing factors SNEV and serine–arginine splic-
ing factor 1 (SRSF1) have demonstrated their role in EC senes-
cence. Thus, upon replicative senescence of human umbilical vein
endothelial cells (HUVECs), a down-regulation of SNEV was
observed (Voglauer et al., 2006). This event takes places concomi-
tantly with down-regulation of the catalytic subunit of the telom-
erase, hTERT, the classic cellular senescent marker. Conversely,
overexpression of SNEV provokes extension of the replicative
lifespan in these cells. In addition to being involved in spliceo-
some assembly and stabilization, SNEV regulates proteasome
function due to its U3-ligase activity, and is involved in DNA
repair (Grillari et al., 2010). Furthermore, the haploinsufﬁciency of
SNEV has been demonstrated using a heterozygous mouse model,
which showed that the proliferative and repopulating capacity of
hematopoietic stemcells from thesemicewas clearly compromised
(Schraml et al., 2008).
The splicing factor SRSF1,orASF/SF2, is the prototypicalmem-
ber of the highly conserved family of serine/arginine-rich proteins
(SR proteins). Structurally, these SR proteins are composed of one
or two RNA recognition motifs plus a C-terminal serine/arginine-
rich domain involved in protein–protein interactions (Figure 1).
During the past decade, the role of SR proteins has been extended
to include a diverse set of cellular processes, including mRNA
nuclear export, mRNA stability and quality control, translation,
maintenance of genomic stability, and oncogenic transformation
(Manley and Krainer, 2010). Within this family, SRSF1 partici-
pates in constitutive and alternative splicing, and in a plethora of
biological processes, including viral infections and cancer (San-
ford et al., 2005; Biamonti and Caceres, 2009). Recently, the role of
SRSF1 in senescence, regulating the expressionof the short isoform
of endoglin, has been described (Blanco and Bernabeu, 2011). In
ECs, SRSF1 promotes retention of the last intron of the endoglin
gene (ENG) by binding to an intronic cis-element that overlaps
with the branch point consensus sequence, interfering with intron
removal (Blanco and Bernabeu, 2011). This retained intron shifts
the open reading frame, incorporating an early stop codon that
produces an alternate cytoplasmic domain shorter than the one
present in the predominantly expressed L-endoglin (Bellon et al.,
1993). This process has been associatedwith aging, contributing to
the development of vascular pathologies including hypertension
andatherosclerosis (Blanco et al., 2008). The involvement of SRSF1
in senescencehas alsobeen studiedusingmouse embryonicﬁbrob-
lasts as a cellular model (Verduci et al., 2010). These authors found
that two microRNAs, miR-28 and miR-505, are induced during
senescence and negatively modulate SRSF1 expression, promoting
cell cycle arrest and/or apoptosis.
SPLICED GENES REGULATED BY SRSF1 AND VASCULAR
AGING
The role of SRSF1 in the endothelial context has been addressed
by analyzing the expression of alternative isoforms of the vascular
endothelial growth factor A (VEGFA) gene. VEGF is expressed as
a disulﬁde-linked homodimer that speciﬁcally acts on ECs. Some
of its biological effects include an increase in vascular permeabil-
ity, induction of growth and migration of ECs (vasculogenesis
and angiogenesis), and inhibition of apoptosis. Of note, VEGFA
encodes two families of isoforms that are generated by alternate
splice-site selection in its terminal exon #8. Thus, selection of the
proximal splice-site (PSS) results in pro-angiogenic VEGF iso-
forms, whereas selection of the distal splice-site (DSS) leads to
anti-angiogenic VEGFb isoforms (Neufeld et al., 1999). Inter-
estingly, SRSF1 is a key regulator in the selection of the PSS,
an event induced by IGF-1 treatment and abolished by TGF-β
stimulus (Nowak et al., 2008; Figure 2A). Also, selection of the
pro-angiogenic PSS by SRSF1 is prompted by changes in the cel-
lular microenvironment such as those that occur in solid tumors,
including a decrease in pH, among others (Elias and Dias, 2008).
Because upon stimulation, SRPK1/2 kinases activate and translo-
cate SRSF1 into the nucleus, it is not surprising to ﬁnd that
inhibition of SRPK1/2 reduced angiogenesis in a mouse model of
retinal neovascularization, launching the potential involvement of
alternative splicing regulation as a therapeutic target in angiogenic
disorders (Nowak et al., 2010; Carter et al., 2011).
In addition to being involved in the selection of splice-sites,
SRSF1 also participates in the skipping of particular exonic
sequences, as in the case of the tissue factor (TF) gene (T3), the
primary initiator of blood coagulation. TF is mainly expressed by
ECs,usually as a transmembrane glycoprotein,but is alsooccasion-
ally produced as a soluble form in response to pro-inﬂammatory
cytokines (Szotowski et al., 2005). The activation and overexpres-
sion of SRSF1, as well as other SR proteins, in ECs favor skipping
exon #5 of TF. Consequently, exon #4 is spliced directly to exon #6,
producing a translational frameshift that leads to the generation
of a soluble variant that contributes to thrombus growth, thus ini-
tiating and propagating the coagulation process (Bogdanov et al.,
2003; Figure 2B).
Recently, the involvement of SRSF1 in alternative splicing of
the lamin A gene (LMNA) has been described (Lopez-Mejia
et al., 2011). LMNA encodes lamins A and C, which are major
components of the nuclear lamina in the inner membrane of
the nuclear envelope. These proteins are involved in essential
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FIGURE 1 |The SR protein family. (A) Scheme representing the level of
homology among human SR proteins (Manley and Krainer, 2010), based on
the result of a multiple sequence alignment using ClustalW2. Alternate
names are in parentheses. Both RS and RRMs are modular domains, which
means that RRMs can be exchanged between SR proteins, and may still bind
to RNA in the absence of the RS domain. The RS domain can bind to a
heterologous RNA-binding domain and be still functional. The asterisk
indicates the SRSF1 member. (B) Structural scheme of SRSF1 showing two
RRM domains (blue) separated by a glycine-rich sequence (dark gray), where
three arginine residues are susceptible to methylation (white dots). The
sequence of the RS domain (violet) is indicated. RRM, RNA recognition motif;
RS, arginine/serine-rich.
FIGURE 2 | Endothelial target genes of SRSF1. (A) Selection of the
proximal (PSS) or distal (DSS) 3′-splice-site determines synthesis of
either the pro- or anti-angiogenic isoform of the VEGFA gene,
respectively. (B)The skipping of exon #5 in the tissue factor (T3) gene
affects the reading frame and generates a soluble, pro-thrombotic
isoform of tissue factor. (C) A reinforcing mutation near a cryptic
5′-splice-site in the LMNA gene truncates the ﬁnal protein (progerin) that
accumulates in the nucleus. (D) Retention of the ﬁnal intron in the ENG
gene alters the reading frame and generates the anti-angiogenic,
pro-ﬁbrotic isoform S-endoglin.
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functions, including DNA replication, transcription, chromatin
organization, and dis/assembly of the nucleus during cell divi-
sion (Worman et al., 2009). Sporadically, a de novo germline
mutation in exon #11 promotes the reinforcement of a weak 5′
splice-site that generates a truncated and pathological version of
lamin A named progerin, which accumulates in cell nuclei in a
tissue-speciﬁc manner (Figure 2C). Interestingly, SRSF1 is crit-
ically involved in the control of the lamin A/progerin splicing
switch. Thus, speciﬁc knock-down of SRSF1 leads to a reduction
in progerin expression, resulting in an important impact on the
lifespan of the animal (Lopez-Mejia et al., 2011). Mutations in
LMNA, that give rise to progerin, are responsible for Hutchinson–
Gilford progeria syndrome, a rare disorder characterized by seg-
mental premature aging and death (Gerhard-Herman et al., 2012).
Progerin accumulates primarily in vascular cells, suggesting its
direct involvement in vascular disease (McClintock et al., 2006), in
agreement with the cardiovascular defects, including accelerated
atherosclerosis, myocardial infarction, and stroke characteristic of
Hutchinson–Gilford progeria syndrome (Trigueros-Motos et al.,
2011; Gerhard-Herman et al., 2012).
The role of SRSF1 in intron retention by the endoglin gene
(ENG) that leads to formation of the senescence-associated S-
endoglin isoform has been demonstrated (Blanco and Bernabeu,
2011). Endoglin is an auxiliary co-receptor for TGF-β expressed
in ECs that plays a critical role in vascular remodeling and angio-
genesis, as illustrated by the fact that mutations in ENG lead to
hereditary hemorrhagic telangiectasia Type 1, a disease charac-
terized by vascular malformations (Lopez-Novoa and Bernabeu,
2010; Shovlin, 2010). While endoglin is predominantly expressed
as the long isoform (L-endoglin) which shows a pro-angiogenic
role, expression during senescence of the alternatively spliced
S-endoglin signiﬁcantly affects the behavior of ECs, promoting
anti-angiogenic and pro-ﬁbrotic phenotypes, and compromising
vasodilator responses (Perez-Gomez et al., 2005; Blanco et al.,
2008; Velasco et al., 2008). In this context, S-endoglin tilts the
TGF-β signaling pathway toward its pro-ﬁbrotic side, via Smad3
signaling, inducing expression of plasminogen activator inhibitor
(PAI)-1, a key regulator of synthesis and deposition of the extra-
cellular matrix in tissue homeostasis (Ghosh and Vaughan, 2012).
Moreover, the TGF-β/S-endoglin signaling pathway represses the
expression of Id1 factor, which is essential for cellular prolifera-
tion (Tang et al., 2002; Blanco et al., 2008). Compatible with this
ﬁnding, elevated levels of TGF-β have been reported in aging vari-
cose veins; these likely favor the ﬁbrotic process and subsequent
venous insufﬁciency (Pascual et al., 2007). BecauseTGF-β-induced
Smad3 is able to interact with transcription factor c-myc, thus
repressing the promoter of the hTERT gene that encodes the cat-
alytic subunit of telomerase, up-regulation of S-endoglin would
be predicted to contribute to endothelial senescence by compro-
mising telomere integrity and arresting the cell cycle (Li and Liu,
2007). It has been postulated that the S-endoglin mRNA, which
bears the last intron, may escape from the activity of the major
spliceosome in the nucleus. Under normal conditions, this intron
would typically be removed by the minor spliceosome in the
cytoplasm, giving rise to the predominant isoform L-endoglin.
However, during senescence, SRSF1 translocates to the cytoplasm,
binding to the consensus SRSF1 cis-element within the branch
point of the S-endoglin mRNA, interfering with the activity of
the minor spliceosome and leading to an increase in the level of
S-endoglin (Figure 2D).
EFFECT OF SENESCENCE-ASSOCIATED STRESS SIGNALS ON
THE ROLE OF SRSF1
Precursor mRNA splicing is one target of several environmental
stress factors, including oxidative stress and ultraviolet radiation,
that frequently cause DNA damage (Biamonti and Caceres, 2009).
Depending on the intensity of the stress signal, cells may react by
activating the check-point pathway mediated by p53 and entering
into cell cycle arrest, which, in turn, prompts senescence (Borras
et al., 2011). Many of these stress stimuli induce the cytoplasmic
accumulation of several splicing factors, including SRSF1 (Bia-
monti and Caceres, 2009), hnRNP A1 (Guil et al., 2006), Slu7
(Shomron et al., 2005), and PTB (Xie et al., 2003). Furthermore,
SRSF1 translocates to the cytoplasm during replicative or stress-
induced senescence, suggesting that SRSF1 is a new senescence
target (Blanco and Bernabeu, 2011).
Serine–arginine splicing factor 1 is a shuttling factor that local-
izes either in the nucleus or the cytoplasm, depending on the
phosphorylation state of its RS domain (Cazalla et al., 2002; San-
ford et al., 2005) and/or the methylation of three arginine residues
between the RRM domains (Sinha et al., 2010; Figure 1B). The
kinase SRPK1 is a major contributor to SRSF1 phosphorylation
and translocation. Under normal conditions, SRPK1 is located
in the cytoplasm where this kinase continuously phosphorylates
SRSF1, favoring its transport to the nucleus. However, some stress
factors may alter the subcellular distribution of SRPK1, trigger-
ing the nuclear import of the kinase (Giannakouros et al., 2011).
Consequently, the cytoplasmic pool of SRSF1 is augmented by the
absence of SRPK1 in the cytoplasm, as well as by the nuclear phos-
phatase activity that facilitates the cytoplasmic export of SRSF1.
Thus, it can be postulated that the cytoplasmic localization of
SRSF1 that occurs during endothelial senescence, whether replica-
tive or induced by stress stimuli, may be due, at least in part, to
nuclear translocation of SRPK1.
Importantly, cytoplasmic SRSF1 is able to modulate the alter-
native splicing of speciﬁc precursor mRNAs, as shown for ENG
in a process that involves the minor spliceosome (m-Sp) machin-
ery (Blanco and Bernabeu, 2011). This m-Sp, also known to be
FIGURE 3 | Summary of the role of SRSF1 in ECs. Several stimuli,
including senescence, induce translocation of SRSF1 to the cytoplasm.
SRSF1 is a key factor that modulates the expression of critical regulators of
vascular physiology, including VEGF, endoglin, tissue factor (TF), and
lamin A.
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U12-dependent, co-exists with the U2-dependent major spliceo-
some (m-Sp) in most organisms (Patel and Steitz, 2003). First
described as responsible for the removal of a rare class of introns
(U12-type), it is currently recognized that m-Sp is also involved in
the processing of standard introns (Sheth et al., 2006) and may be
localized in the cytoplasm (Konig et al., 2007). The m-Sp contains
four unique small nuclear ribonucleic acids (snRNAs): U11, U12,
U4atac, and U6atac, which are paralogs of the U1, U2, U4, and
U6 snRNAs of the m-Sp, respectively, while U5 snRNA is shared
between the two spliceosomes. While m-Sp is able to splice and
remove the intron encoded in S-endoglin, the cytoplasmic local-
ization of SRSF1 during endothelial senescence interferes with this
splicing,promoting intron retention (Blanco andBernabeu,2011).
This is in agreement with the ﬁndings that: (i) depletion of pro-
tein components essential form-Sp activity leads to cellular growth
arrest (Will et al., 2004); and (ii) during cell senescence, changes in
gene expression levels affect the composition and activity of m-Sp
(Meshorer and Soreq, 2002; Harries et al., 2011).
CONCLUSION
Numerous and increasing efforts are focused on aging research,
to try to elucidate its underlying molecular mechanisms. Aging is
one of themajor risk factors for the development of cardiovascular
diseases, and is associated with cellular senescence of the vascular
endothelium. In this context, there is growing interest in the mol-
ecular components that orchestrate the modulation of alternative
splicing events in senescent ECs. Due to its senescence-induced
cytoplasmic localization, the splicing factor SRSF1 can be consid-
ered as a new marker for endothelial senescence. In addition, the
cytoplasmic SRSF1 regulates alternative splicing of the endoglin
pre-mRNA, leading to the senescence-associated S-endoglin iso-
form,which contributes to a senescent environment in the vessels.
The data summarized in this review support the link between
SRSF1 and senescence, and also suggest the existence of a com-
mon genetic program involving alternative splicing of a cluster of
genes, including ENG, VEGFA, T3, and LMNA, whose resulting
variants orchestrate vascular functions (Figure 3). Deciphering
this senescent program will shed light on new therapeutic targets
for cardiovascular diseases.
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